Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youth treated with tenofovir disoproxil fumarate

Authors: HAVENS, PETER - University Of Wisconsin; HAZRA, ROHAN - National Institutes Of Health (NIH); Stephensen, Charles; KISER, JENNIFER - University Of Colorado; FLYNN, PATRICIA - St Jude Children’s Research Hospital; WILSON, CRAIG - University Of Alabama; RUTLEDGE, BRANDY - Westat Inc; BETHEL, JAMES - Westat Inc; PAN, CYNTHIA - University Of Wisconsin; Woodhouse, Leslie; Van Loan, Marta; LUI, NANCY - Westat Inc; LUJAN-ZILBERMANN, JORGE - University Of South Florida; BAKER, ALYNE - Tulane University; KAPOGIANNIS, BILL - National Institutes Of Health (NIH); GORDON, CATHLEEN - Brown University; MULLIGAN, KATHLEEN - University Of California

Submitted to: Antiviral Therapy
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 2/4/2014
Publication Date: 2/17/2014
Citation: Havens, P.L., Hazra, R., Stephensen, C.B., Kiser, J., Flynn, P.M., Wilson, C.M., Rutledge, B., Bethel, J., Pan, C., Woodhouse, L.R., Van Loan, M.D., Lui, N., Lujan-Zilbermann, J., Baker, A., Kapogiannis, B.G., Gordon, C.M., Mulligan, K. 2014. Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youth treated with tenofovir disoproxil fumarate. Antiviral Therapy. DOI: 10.3851/IMP2755.

Interpretive Summary: Tenofovir (TDF) is an antiretroviral drug associated with phosphaturia and elevated 1,25 dihydroxy vitamin D (1,25-OH(2)D). Fibroblast growth factor-23 causes phosphaturia and increases in response to elevated 1,25-OH(2)D. Vitamin D binding protein (VDBP) binds to 1,25-OH(2)D, decreasing biologic activity, and is elevated in persons with higher plasma tenofovir concentrations. We compared FGF23 and VDBP before and after vitamin D3 (VITD) supplementation in youth treated with combination antiretroviral therapy (cART)containing or not containing TDF. A randomized controlled trial in HIV+ youth ages 18-25 years enrolled participants based on cART treatment with TDF (TDF, N=118) or without TDF (n-TDF, N=85) and randomized within those groups to VITD (50,000 IU every four weeks) or placebo (PL). We measured FGF23 and VDBP and calculated free 1,25-OH(2)D at baseline and week 12, and compared changes by TDF treatment and VITD randomized group. At baseline, serum FGF23 concentration showed a quadratic relationship with 1,25-OH(2)D most pronounced in the TDF group. At week 12, total and free 1,25-OH(2)D increased in the VITD but not PL groups, independent of TDF use. FGF23 increased in the TDF group receiving VITD, but there was no FGF23 change in the no-TDF group receiving VITD or the PL groups. The adjusted mean change in FGF23 from baseline to week 12 was +7.7 pg/ml in the TDF/VITD group, compared to -1.7 (no-TDF/VITD, p=0.010); -1.3 (TDF/PL, p=0.006); and +1.1 (no-TDF/PL, p=0.035). These results suggest that TDF-containing cART may alter the FGF23 response to vitamin D supplementation in HIV-infected youth

Technical Abstract: Tenofovir (TDF) is associated with phosphaturia and elevated 1,25 dihydroxy vitamin D (1,25-OH(2)D). Fibroblast growth factor-23 causes phosphaturia and increases in response to elevated 1,25-OH(2)D. Vitamin D binding proetin (VDBP) binds to 1,25-OH(2)D, decreasing biologic activity, and is elevated in persons with higher plasma tenofovir concentrations. We compared FGF23 and VDBP before and after vitamin D3 (VITD) supplementation in youth treated with combination antiretroviral therapy (cART)containing or not containing TDF. A randomized controlled trial in HIV+ youth ages 18-25 years enrolled participants based on cART treatment with TDF (TDF, N=118) or without TDF (n-TDF, N=85) and randomized within those groups to VITD (50,000 IU every four weeks) or placebo (PL). We measured FGF23 and VDBP and calculated free 1,25-OH(2)D at baseline and week 12, and compared changes by TDF treatment and VITD randomized group. At baseline, serum FGF23 concentration showed a quadratic relationship with 1,25-OH(2)D most pronounced in the TDF group. At week 12, total and free 1,25-OH(2)D increased in the VITD but not PL groups, independent of TDF use. FGF23 increased in the TDF group receiving VITD, but there was no FGF23 change in the no-TDF group receiving VITD or the PL groups. The adjusted mean chnage in FGF23 from baseline to week 12 was +7.7 pg/ml in the TDF/VITD group, compared to -1.7 (no-TDF/VITD, p=0.010); -1.3 (TDF/PL, p=0.006); and +1.1 (no-TDF/PL, p=0.035). These results suggest that TDF-containing cART may alter the FGF23 response to vitamin D supplementation in HIV-infected youth